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ABSTRACT
We addressed trastuzumab emtansine (T-DM1) efficacy in HER2+ metastatic 
breast cancer patients treated in real-world practice, and its activity in pertuzumab-
pretreated patients. We conducted a retrospective, observational study involving 
23 cancer centres, and 250 patients. Survival data were analyzed by Kaplan Meier 
curves and log rank test. Factors testing significant in univariate analysis were 
tested in multivariate models. Median follow-up was 15 months and median T-DM1 
treatment-length 4 months. Response rate was 41.6%, clinical benefit 60.9%. Median 
progression-free and median overall survival were 6 and 20 months, respectively. 
Overall, no differences emerged by pertuzumab pretreatment, with median 
progression-free and median overall survival of 4 and 17 months in pertuzumab-
pretreated (p=0.13), and 6 and 22 months in pertuzumab-naïve patients (p=0.27). 
Patients who received second-line T-DM1 had median progression-free and median 
overall survival of 3 and 12 months (p=0.0001) if pertuzumab-pretreated, and 8 and 
26 months if pertuzumab-naïve (p=0.06). In contrast, in third-line and beyond, median 
progression-free and median overall survival were 16 and 18 months in pertuzumab-
pretreated (p=0.05) and 6 and 17 months in pertuzumab-naïve patients (p=0.30). 
In multivariate analysis, lower ECOG performance status was associated with 
progression-free survival benefit (p<0.0001), while overall survival was positively 
affected by lower ECOG PS (p<0.0001), absence of brain metastases (p 0.05), and 
clinical benefit (p<0.0001). Our results are comparable with those from randomized 
trials. Further studies are warranted to confirm and interpret our data on apparently 
lower T-DM1 efficacy when given as second-line treatment after pertuzumab, and on 
the optimal sequence order.
INTRODUCTION
HER2 is overexpressed/amplified in about 15-20% 
of breast cancers, and is related to poor prognosis [1, 2]. 
Trastuzumab has dramatically changed the outcome of 
these patients, both in the early and advanced setting [3–
5]. Unfortunately, all metastatic patients will ultimately 
develop resistance [6]. Further HER2 blocking agents, 
such as lapatinib combined with capecitabine, showed 
activity in trastuzumab pretreated patients [7], and the 
combination trastuzumab-lapatinib was associated with 
improved overall survival (OS) compared with lapatinib 
alone [8]. Trastuzumab emtansine (T-DM1) is a HER2-
targeted antibody-drug conjugate comprising DM1, an 
antimicrotubule maytansine derivative, conjugated to 
trastuzumab via a stable thioether linker [9]. T-DM1 
efficacy in trastuzumab-resistant patients was confirmed 
in phase II-III trials [10–14] and, in the EMILIA trial, 
it significantly prolonged progression-free survival 
(PFS) and OS over lapatinib-capecitabine [12]. In 
the TH3RESA trial, PFS and OS were significantly 
improved by T-DM1 over treatment of physician’s 
choice in heavily pretreated metastatic breast cancer 
(MBC) patients [13, 14], making T-DM1 the mainstay 
of treatment in patients previously treated with taxane 
and trastuzumab.
Pertuzumab is a humanized monoclonal antibody 
binding HER2 at a site distinct from that of trastuzumab 
and inhibiting HER2 heterodimerization [15]. In 
the CLEOPATRA trial, pertuzumab, combined with 
trastuzumab and docetaxel, showed longer PFS and OS 
over trastuzumab-docetaxel as first-line treatment, being 
actually the established first-line treatment in HER2 
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positive (HER2+) MBC [16, 17]. Unfortunately, evidence 
on T-DM1 efficacy following pertuzumab-trastuzumab-
docetaxel is still limited, since available data are mostly 
from heavily pretreated, pertuzumab-naïve patients. 
Recently, a retrospective study evaluated T-DM1 activity 
in 78 pertuzumab-pretreated patients: data showed lower 
response rate (RR) than usually reported in trastuzumab-
resistant patients, even if T-DM1 was delivered for more 
than 6 months in one third of the patients [18].
We herein present the results from a multicenter, 
observational study carried out according to a retrospective 
design. In this trial, we aimed at testing T-DM1 efficacy 
in a non selected cancer patients population of HER2+ 
MBC to yield evidence in support of its use in real-world 
practice.
RESULTS
We retrospectively identified 250 HER2+ MBC 
patients treated with T-DM1 from February 2013 through 
July 2016 at 23 Italian cancer centers. Main patient and 
tumor characteristics are reported in Table 1. Median age 
was 56 years, median ECOG PS 0. Sixty-seven patients 
(26.8%) were metastatic at cancer diagnosis. One hundred 
and seventy-eight patients had “Luminal B” tumors 
expressing both (50.4%) or one hormonal receptor/s 
(20.8%), whereas 72 (28.8%) showed “HER2-enriched” 
tumors i.e., both ER/PgR negative cancers. Ninety-six 
patients (38.4%) had received trastuzumab-based regimens 
in the early setting (neoadjuvant and/or adjuvant). Among 
the remaining 154 (61.6%) patients, 67 were metastatic 
at diagnosis, 40 had been treated before trastuzumab 
registration, and 47 were HER2- at diagnosis. All but 
13 patients (5.2%) had been previously treated with one 
or more HER2-targeted therapies for advanced disease, 
including trastuzumab/chemotherapy and/or endocrine 
therapy (ET), lapatinib-capecitabine, pertuzumab-
trastuzumab-taxane. Forty-seven (18.8%) patients were 
pretreated with pertuzumab-based regimens. The median 
number of previous chemotherapy lines for advanced 
disease was 2 (0-8). The median number of previous ET 
lines with/without trastuzumab for advanced disease was 
1 (0-4). At T-DM1 starting, 59.2% of the patients had 
visceral metastases, 24.4% showed asymptomatic brain 
metastases, 4.4% showed exclusively bone involvement, 
and 73.2% had multiple metastatic sites. Thirteen patients 
(5.2%) received T-DM1 as first-line treatment due to 
recurrence while on or within 6 months from adjuvant 
treatment, 100 (40%) patients received T-DM1 as second-
line, 137 (54.8%) patients were treated in more advanced 
lines.
All but 5 patients were evaluable for efficacy. 
Among them, 3 refused treatment, while 2 were lost to 
follow up. Median (m) follow up was 15 months (95%CI, 
13-16), and m T-DM1 treatment duration was 4 months 
(range, 1-29), with 20% of patients having being treated 
for more than 6 months. Among the 245 evaluable 
patients, 14 (5.7%) had a complete response (CR) and 
95 (38.8%) a partial response (PR), for an overall RR 
of 44.5% (95%CI, 38.3-50.7). Stable disease (SD) was 
recorded in 59 patients (24.1%). Clinical benefit (CB), 
i.e., response or SD lasting ≥6 months, was observed 
in 145 (59.2%) patients (95%CI, 53.0-65.3). Objective 
responses and CB by molecular subtype did not differ 
significantly (Supplementary Table 1). Among the 96 
patients who received neoadjuvant/adjuvant trastuzumab, 
4 (4.2%) had a CR and 44 (45.8%) a PR, for an overall 
RR of 50.0% (95%CI, 40-60). Stable disease was 
recorded in 23 patients (24.0%). Clinical benefit was 
observed in 61 (63.5%) patients (95%CI, 53.9-73.2). 
Overall, no differences in responses emerged by disease 
site (viscera 41%, bone 39%, soft tissue 42%; p=0.95) 
or by T-DM1 treatment-line, since they were 46.2%, 
50%, and 39.6% in first, second, third-line and beyond, 
respectively (p=0.28).
In the overall patient population, mPFS and 
mOS were 6 (95%CI, 5-7) and 20 months (95%CI, 
14-26), respectively (Figure 1), with no differences by 
molecular subtype, being mPFS 5.8 months (range, 4.9-
6.8) in “Luminal B”, and 7 months (range, 4.7-9.2) in 
“HER2 enriched” tumours (p=0.29) (Supplementary 
Table 2). Median OS was 17.8 (range, 13.9-21.8) in 
“Luminal B”, and 26 months (range, 16-36) in “HER2 
enriched” cancers (p=0.14) (Supplementary Table 
2 and Supplementary Figure 1). In patients treated 
with neoadjuvant/adjuvant trastuzumab, median PFS 
and median OS were 7 (95%CI, 5-9) and 26 months 
(95%CI, 17-34). Median PFS and OS by metastatic site 
were 7 (95%CI, 5-9) and 20 months (95%CI, 14-27) in 
patients without visceral involvement, and 5 (95%CI, 
4-6) and 22 months (95%CI, 8-35) in patients with 
visceral metastases (p=0.07 and p=0.69, respectively). 
Progression-free survival by T-DM1 treatment-line 
ranged from 3 to 11 months, with patients treated in 
third-line showing the most favorable outcome. Median 
OS was 20 months (95%CI, 13-27) as first-line, 26 
months (95%CI, 15.6-36.3) in second-line, and 17.8 
months (95%CI, 14-29) when T-DM1 was administered 
in more advanced lines (Table 2) (p=0.60).
An exploratory subgroup analysis was performed 
in pertuzumab-pretreated patients (47 over 250, Table 3). 
Overall, RR and CB obtained from T-DM1 in pertuzumab-
pretreated patients were 40.2% (95%CI, 26.4-54.4), and 
48.9% (95%CI,34.6-63.2), respectively. In pertuzumab-
naïve patients, RR and CB were 44.3% (95%CI, 37.5-
51.2) and 60.1% (95%CI, 55.4-66.8). Differences were not 
significant (p=0.75 and p=0.22). Patients who achieved a 
response/stabilization to previous pertuzumab tended to 
replicate response/stabilization under T-DM1, even if at 
a not significant extent (p=0.72, Supplementary Table 3) 
and independently on T-DM1 line administration. Overall, 
mPFS and mOS to T-DM1 in pertuzumab-pretreated 
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Table 1: Main baseline characteristics of the study population (number: 250)
Characteristics Patients, number (%)
Age
Median (range)
56 (29-82)
Histology
Ductal
Lobular
Other
218 (87.2)
15 (6)
17 (6.8)
Metastatic at diagnosis
Yes
No
67 (26.8)
183 (73.2)
Grading
1-2
3
Unknown
74 (29.6)
160 (64)
16 (6.4)
HER2-positive at initial diagnosis
Yes
No
203 (81.2)
47 (18.8)
Molecular subtype
Triple-positive
ER or PgR positive
HER2-enriched
126 (50.4)
52 (20.8)
72 (28.8)
ECOG Performance status
0
1
2
140 (56)
91 (36.4)
19 (7.6)
Neo-adjuvant chemotherapy
Yes
Not
60 (24)
190 (76)
Neoadjuvant/adjuvant trastuzumab
Yes
Not
96 (38.4)
154 (61.6)
Adjuvant chemotherapy
Yes
No
144 (57.6)
106 (42.4)
Prior pertuzumab-trastuzumab-taxane treatment
Yes
Not
47 (18.8)
203 (82.2)
T-DM1 administered as
First-line
Second-line
Third-line and beyond
13 (5.2)
100 (40.0)
137 (54.8)
Metastatic sites
Visceral
Brain
Other
148 (59.2)
61 (24.4)
41 (16.4)
Number of metastatic sites
1
2
≥3
67 (26.8)
142 (56.8)
41 (16.4)
Oncotarget5www.impactjournals.com/oncotarget
patients were 4 (95%CI, 2-7) and 17 months (95%C.I., 
11-22), respectively In pertuzumab-naïve patients, mPFS 
was 6 months (95%CI, 5-7), and mOS was 22 months 
(95%CI, 14-29). These differences were not significant 
(p=0.13 and 0.27, respectively). We further analyzed the 
impact of pertuzumab-pretreatment by line of T-DM1 
administration. Pertuzumab-pretreated patients who 
received T-DM1 as second-line (39 patients), showed a 
mPFS of 3 months (95%CI, 2-4), whereas 62 patients, who 
did not receive previous pertuzumab but other antiHER2-
based treatments and received second-line T-DM1, had a 
mPFS of 8 months (95%CI, 4-12) (p=0.0001) (Figure 2, 
Supplementary Table 4). Results were confirmed when 
adjusting for propensity score (Supplementary Figure 
2). This minimizes the chances that the differences 
observed between the groups compared were driven 
by unevenly distributed baseline characteristics for the 
patients included. These latter characteristics are shown 
in Supplementary Table 5. Median OS for pertuzumab-
pretreated patients who received second-line T-DM1 was 
12 months (95%CI, 9-15), whereas it was 26 months 
(95%CI, 16-36) in pertuzumab-naïve patients (p=0.06) 
(Figure 2). The small subset of 8 patients who received 
prior pertuzumab and were treated with T-DM1 as third-
line and beyond, showed a longer mPFS compared 
with those treated with second-line T-DM1 following 
pertuzumab/trastuzumab (16 vs 3 months, p=0.004). 
In more details, 4 patients progressed on T-DM1 at 
3, 8, 11 and 16 months. The remaining 4 patients were 
progression-free at 6 (2 patients), 15 (1 patient) and 24 
months (1 patient). Moreover, patients receiving second-
line T-DM1 after pertuzumab, showed a significantly 
shorter mOS than that reported in pertuzumab-pretreated 
patients receiving T-DM1 beyond the second-line (12 
vs 18 months, p=0.04). One-hundred and twenty-five 
pertuzumab-naïve patients receiving T-DM1 beyond the 
second-line had a mPFS of 6 months (95%CI, 4-7), and 
a mOS of 17 months (95%CI, 12-22), with no relevant 
statistical differences (p=0.05 and p 0.30, respectively) 
(Figure 2, Supplementary Table 4).
In multivariate analysis including the overall 
population (Table 4), the only factor related to PFS 
benefit was lower ECOG PS (p<0.0001), while OS was 
positively affected by lower ECOG PS (p=0.001), CB 
(p<0.0001), and absence of brain metastases at baseline 
(p=0.05).
Overall, disease progression involved the central 
nervous system (CNS) in 44 (17.6%) patients, 11.6% 
in patients without previous brain metastases, 36.1% in 
patients with previous CNS involvement. Patients with 
CNS metastases at baseline (61 patients) showed similar 
mPFS compared to the overall population (6 months, 
95%CI, 4-8), while mOS was shorter (16 months, 95%CI, 
12-19).
Data on toxicity were only partially available due to 
the observational and retrospective design, and are showed 
in Supplementary Table 6. Mild and transient cardiac 
dysfunction was observed in 4 patients (1.6%).
Figure 1: Progression-free survival (PFS, A) and overall survival (OS, B) in the overall population. No: number.
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Table 3: T-DM1 responses according to pertuzumab-pretreatment
Pertuzumab pre-treated 
patients (95%CI)
Pertuzumab naïve patients 
(95%CI) p
Response rate 40.2% (26.4-54.4) 44.3% (37.5-51.2) 0.75
Clinical benefit rate 48.9% (34.6-63.2) 60.1% (55.4-66.8) 0.22
Abbreviations: 95%CI: confidence interval.
Table 2: T-DM1 progression free survival (PFS) and overall survival (OS) according to treatment line
T-DM1 treatment line mPFS (months) 95%CI mOS(months) 95%CI N of pts
I 7 6-8 20 13-27 13
II 6 5-7 26 15.6-36.3 98
III 11 6-16 18 13-23 65
IV 6 4-8 18 8-28 38
V and beyond 3 2.7-3.3 16 10-21 31
Abbreviations: 95%CI: confidence interval; m: median; N: number; pts: patients.
Figure 2: Progression-free survival (A) and overall survival (B) in patients who received T-DM1 as second-line or beyond according to 
pertuzumab pre-treatment. PFS: progression-free survival; OS: overall survival; No: number.
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DISCUSSION
We analyzed data from 250 HER2+ MBC patients 
treated with T-DM1 at 23 Italian cancer centers. On 
the whole, our results on T-DM1 activity expressed 
in terms of RR and CB favorably compare with those 
from phase II-III trials [11–13]. Overall, our data seem 
not to provide support to differences in T-DM1 efficacy 
by prior exposure to pertuzumab. However, generally, 
patients with more favorable outcomes to pertuzumab 
tended to show favorable outcomes also to T-DM1, 
although at a not statistically significant extent. When 
stratifying analysis by line of T-DM1 administration, 
pertuzumab-pretreated patients who received T-DM1 in 
second-line showed worse survival outcomes compared to 
pertuzumab-naïve patients. Conversely, when T-DM1 was 
administered in more advanced lines, mPFS was slightly 
better in pertuzumab-pretreated patients. Interestingly, 
no significant differences emerged when patients having 
received T-DM1 in second vs more advanced lines were 
compared by mPFS following exposure to pertuzumab. 
This may suggest that patients from the subsets compared 
do not necessarily represent two distinct populations with 
different sensitivity to HER2 blocking agents.
Based on our data, T-DM1 efficacy seems 
independent on the line of treatment in pertuzumab-naïve 
patients, whereas, in pertuzumab-pretreated patients, 
T-DM1 showed greater efficacy when not administered 
immediately after pertuzumab-based treatment. Several 
keys of interpretation may be provided in an attempt to 
clarify our findings. However, the restricted number of 
patients invites extreme caution in interpreting our results, 
since pertuzumab-pretreated patients were only 47, and 
patients treated with T-DM1 beyond the second-line only 
8. In addition, the use of pertuzumab within a 3-drug 
combination including trastuzumab and a taxane may add 
a substantial degree of complexity to the interpretation 
of our findings. We may hypothesize that patients who 
received T-DM1 following multiple HER2 blocking-based 
treatments had an intrinsically less aggressive disease 
that allowed a higher number of therapeutic lines. This 
hypothesis may be somewhat supported by the results 
of correlation analysis between the number of lines of 
treatment and survival outcomes in subgroups defined 
upon previous exposure to pertuzumab. In brief, in the 
subgroup of patients previously exposed to pertuzumab, 
we observed a direct correlation between the number of 
previous lines of treatment and both mPFS (R = 0.50, p 
= 0.003) and mOS (R=0,61, p=0.02). When considering 
patients naïve to pertuzumab, the number of lines of 
treatment and mPFS were inversely related (R = -0.23, 
p=0.005), while no relevant associations emerged with OS 
(p=0.94) (data available upon request).
It is also plausible that when T-DM1 administration 
immediately follows pertuzumab-based combinations 
because of resistance occurrence, its activity may suffer 
from a transient impaired access of this drug to the 
binding site. This latter may be hypothesized based on 
the lack of HER2 receptors on tumor cells surface due 
to pertuzumab-trastuzumab-mediated internalization 
with endocytic destruction, or to inefficient prevention 
of proteolitic shedding of extracellular domain, resulting 
in truncated forms (p95HER2) [19–23]. Conversely, the 
8 pertuzumab-pretreated patients who received other 
regimens prior to T-DM1, (such as lapatinib-based 
combination, or chemotherapy plus trastuzumab), could 
have benefited the most from subsequent T-DM1 because 
of the re-expression of HER2 receptors on tumor cells 
surface, partially related to lapatinib [24, 25], or simply 
due to the time-interval elapsed between pertuzumab and 
T-DM1 administration. Moreover, a chemotherapeutic 
agent not directly conjugated to trastuzumab but given in 
combination with it, in patients with a transient limited 
access to HER2 receptors, may be efficacious even if 
administered immediately after pertuzumab/trastuzumab. 
Conversely, the activity of T-DM1 is strictly related to the 
presence of surface HER2 receptors, since after T-DM1 
binds to HER2 receptors, the HER2-T-DM1 complex 
enters into cancer cells through receptor-mediated 
endocytosis, and releases DM1. The limits imposed 
by the restricted number of patients in our subgroup 
analysis, along with the retrospective nature of our study 
design, call for confirmation of our findings in future, 
prospectively designed and opportunely sized studies.
Table 4: Multivariate analysis
PFS HR 95%CI P
ECOG PS(1-2 vs 0) 2.21 1.64-2.98 <0.0001
OS HR 95%CI P
ECOG PS(1-2 vs 0) 2.28 1.41-3.68 0.001
Brain metastases(yes vs no) 1.60 1-2.57 0.05
CB(no vs yes) 3.83 2.42-6.06 <0.0001
Abbreviations: HR: hazard ratio; 95%CI: confidence interval; PS: performance status; CB: clinical benefit.
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Because pertuzumab and T-DM1 have been recently 
approved for first and second-line treatment of HER2 
MBC, several patients have not been treated with these 
agents yet, making it difficult a truly comprehensive 
evaluation of the efficacy of the optimal sequence order. 
A recent report on 78 pertuzumab-pretreated patients 
treated with T-DM1 in routine practice as first, second 
and more advanced lines [18] showed lower rates of 
responses compared to previous studies of trastuzumab-
resistant patients, even if 30.8% of patients received 
T-DM1 for at least 6 months. Twenty-six patients were 
treated as first or second-line and 52 as more advanced 
lines. When T-DM1 was administered as first or second-
line, the authors reported a clinical response of 23.1%, and 
a prolonged duration on therapy in 34.6% of patients. In 
more advanced lines, T-DM1 showed a clinical response 
of 15.4% and a prolonged duration on therapy in 28.8% of 
patients. In patients pretreated with lapatinib the response 
was 11.1% and T-DM1 was administered for more than 6 
months in 27.8% of patients. There are some differences in 
the patients’ populations from these two studies. Primarily, 
the percentage of patients presenting with de novo stage 
IV disease (44% in the Dzimitrowitz study and 27% in 
the present study); moreover, our patients exhibited more 
often hormonal receptor positive tumors (71.2% versus 
62.2%). In addition, in the study from Dzimitrowitz, when 
reporting results on T-DM1 activity, no distinction is made 
between first- or second-line of administration. Another 
recent report from the T-PAS expanded access study of 
T-DM1 in heavily pretreated patients, showed a mT-DM1 
duration of 5.0 months and a RR of 25.6%, with a safety 
profile comparable with that of phase II-III studies [26]. 
However, these patients were all pertuzumab-naïve.
At present, few data are available regarding efficacy 
of T-DM1 in breast cancer patients with CNS metastases. 
In our study 22 patients developed CNS as first-site of 
progression (11.6%), whereas twenty-two (36.1%) patients 
with known and pretreated CNS metastases developed 
progression at CNS site. Overall, mPFS in patients with 
CNS metastases at baseline was similar to that of patients 
without CNS metastases; conversely, mOS was shorter. In 
a multicenter retrospective study of T-DM1 administered 
to patients with known CNS metastases, this drug activity 
was confirmed, with results comparable to those of 
patients without brain metastases, except for OS [27]. 
Conversely, in a retrospective analysis of the EMILIA 
trial in patients with known CNS metastases, a significant 
improvement in OS was observed in the T-DM1 arm 
versus lapatinib-capecitabine, whereas PFS, and the rate 
of progression at CNS site, were similar in the two arms 
[28]. A more exhaustive analysis on T-DM1 activity in 
our patient population with known or developing brain 
metastases is ongoing, and will be soon reported in a 
separate manuscript.
Toxicity data from our patient population were only 
partly available, due to retrospective study design applied 
to the real world setting. Overall, treatment with T-DM1 
was generally well tolerated. No grade 4 toxicities were 
recorded, and grade 3 adverse events were uncommon, 
mostly fatigue, thrombocytopenia, increase in serum 
transaminases and nausea, with no new safety issue.
The present study has some important limitations, 
mostly related to its retrospective design, and to the 
heterogeneity of the study population. Indeed, the 
fairly high number of participating centers and the 
real-world practice setting certainly concurred to add 
heterogeneity to our study population compared to 
patients from randomized clinical studies. Moreover, in 
retrospective studies, the RECIST criteria and timing at 
tumor re-assessment are less stringent and precise than 
in prospective trials. In addition, although our study 
population may seem not particularly limited in size, 
caution must be paid when interpreting results from our 
subgroup analyses. Indeed, the limited number of patients 
included in subsets defined upon the variables of interest 
may importantly limit the statistical power of some of the 
analyses performed and the generalizability of the results 
obtained.
When compared by prior exposure to pertuzumab, 
patients differed significantly in terms of age 
(Supplementary Table 5). Pertuzumab-naïve patients 
also showed a lower rate of visceral metastases, 
although at a not significant extent. To minimize the 
above reported selection bias, survival analyses were 
adjusted by propensity score. However, case matching 
by age and visceral metastases could not remove other 
potentially important causes of bias from unknown 
confounders possibly including prior/subsequent 
therapies, comorbidities, and differences in disease 
biology. In these regards, it is worth mentioning that data 
concerning co-morbidities and safety were not available 
for analysis purposes. Furthermore, the lack of punctual 
details concerning drug exposure in terms of changes 
eventually occurred in the administration schedule may 
have somewhat limited our ability to correctly interpret 
our study results. More generally, missing data on 
variables and outcomes of possible interest, i.e., toxicity, 
derive from our limited ability to gather all the relevant 
information for depicting a complete patient profile while 
working in a real world setting, particularly when relying 
on a retrospective approach.
Our study also has some relevant strengths. First, it 
reports outcomes of T-DM1 treatment in a large cohort of 
HER2+ MBC patients treated outside clinical trials in the 
real-world setting, thus coherently reproducing the daily 
practice. Moreover, to our knowledge, this is the first study 
on T-DM1 activity reporting results in light of pertuzumab 
pretreatment and lines of T-DM1 administration. Even if 
numbers are relatively small and results are not from a 
randomized prospectively designed study, our report on 
the apparently lower efficacy of T-DM1 when this latter is 
administered right after pertuzumab-trastuzumab deserves 
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further investigations. Since HER2+ breast cancer evolves 
under selective pressure of new targeted agents, it is of 
paramount importance recognizing unexpected resistance 
pathways, partially related also to novel treatments 
sequence order.
At present, the definition of the right sequence 
of HER2 blocking agents remains a challenge. While 
waiting for the results of the ongoing prospective 
trial testing T-DM1 in pertuzumab-pretreated patients 
(NCT01835236), our study may offer some interesting 
clues on a non-selected HER2+ MBC population treated 
with T-DM1 after multiple HER2 blocking agents-based 
therapies.
PATIENTS AND METHODS
We retrospectively identified patients who received 
T-DM1 at various Italian oncologic centres. The follow-
up was stopped in August 2016, that is, when a median 
follow up of at least 12 months was reached and statistical 
analysis performed. Our primary objective was evaluating 
T-DM1 efficacy in a non-selected patient population. 
Secondarily, we assessed its activity in pertuzumab-
pretreated patients. T-DM1 was administered according to 
guidelines until disease progression, unacceptable toxicity, 
or patient refusal. Treatment efficacy was evaluated 
by conventional RECIST criteria. Toxicity data, when 
available, were graded using the NCI-CTCAE (version 
4.0). Our study was approved by local Ethic Committees 
and conducted according to the Helsinki Declaration. All 
the patients released a written informed consent.
Data collection
Medical records were retrieved for demographic, 
clinical and molecular features, previous treatments 
and related outcomes, number and site of metastases at 
the time of T-DM1 starting, tumor response, toxicity, 
date at disease progression, date at the last follow-up or 
death. Pathology assessment was performed in surgical 
specimens of primary tumors at the participating centers. 
When missing, the molecular features were centrally 
evaluated in formalin-fixed, paraffin-embedded tissue 
sections. Anonymized data were entered into a dedicated 
database.
Statistical analysis
Variables were assessed by Pearson Chi-Square test 
or Fisher Exact test. Their impact on survival was tested 
in Cox uni/multivariate models. Significance was set at 
p≤0.05. The multivariate Cox hazard model was built 
using stepwise regression (forward selection). Enter and 
remove limit were p=0.10 and p=0.15. The following 
variables were considered: age, ECOG PS, histology, ki67, 
molecular subtype, stage at diagnosis, type of surgery, 
adjuvant and number of advanced treatments, disease-
free survival, pertuzumab pretreatment, type and number 
of metastatic sites and treatment response. Survival was 
addressed by the Kaplan–Meier method and log-rank test. 
Significance was defined at p≤0.05 level.
The effect of covariates potentially acting as 
confounders in a non-randomized cohort was minimized 
by propensity score match, which allowed to create patient 
groups who were similarly likely to receive a given 
treatment based on their baseline characteristics [29]. 
SPSS software was used for statistical evaluations (SPSS 
version 21.0, SPSS Inc., Chicago, Illinois, USA).
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